Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status 0 or 1~* Clinically stage 2 or 3 with histologically proven lymph node involvement~* Tumor or lymph node greater than 1.5 cm~Exclusion Criteria:~* Pregnancy or lactation~* Prior chemotherapy or radiotherapy for any malignancy~* Documented history of cardiac disease contraindicating anthracyclines~* Currently active infection

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FEC3-D3 (Type: ACTIVE_COMPARATOR): 3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks
- AC4-D4 (Type: NO_INTERVENTION): 4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).